Novavax NVAX Licensing, royalties, and other — Total Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Novavax in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The official record: Novavax’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Novavax's licensing, royalties, and other — total revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Novavax's licensing, royalties, and other — total revenue?
- Novavax (NVAX) reported licensing, royalties, and other — total revenue of $97.31M in Q1 2026.
- How has Novavax's licensing, royalties, and other — total revenue changed year-over-year?
- Novavax's licensing, royalties, and other — total revenue increased by 116.4% year-over-year, from $44.98M to $97.31M.
- What is the long-term trend for Novavax's licensing, royalties, and other — total revenue?
- Over 2 years (2022 to 2025), Novavax's licensing, royalties, and other — total revenue has grown at a 215.7% compound annual growth rate (CAGR), from $43.99M to $438.44M.
- What does licensing, royalties, and other — total revenue mean?
- This metric represents the total revenue generated from intellectual property licensing agreements, royalty payments from partners, and miscellaneous service or collaboration fees. It reflects the company's ability to monetize its proprietary technology platform and vaccine candidates through external partnerships rather than direct product sales. This revenue stream is critical for assessing the company's success in leveraging its research and development output to create recurring, non-dilutive income.